Global Xerostomia Therapeutics Market Analysis, Drivers, Restraints, Opportunities, Threats, Trends, Applications, and Growth Forecast to 2027

Global Xerostomia Therapeutics Market Overview :

“The global Xerostomia Therapeutics Market size is expected to be worth around US$ xx Billion by 2021 from US$ X.xx million in 2031, growing at a CAGR of X.x% during the forecast period 2021 to 2031.”

Xerostomia is defined as medical condition causing dry mouth resulting from reduced or absent saliva flow in the mouth. It is caused due to a side effect of a radiation to the head and neck, or a side effect of a wide variety of medications over prolong administration.

Drug types that are used to treat xerostomia include antihistamines, antihypertensive, tricyclic antidepressants, and sedatives. Diagnosis of xerostomia is based on evidence obtained from the patient’s history, an examination of the oral cavity and/or sialometry, and a simple procedure that measures the flow rate of saliva.

Key factors expected to drive growth of the global xerostomia therapeutics market is increasing incidence and prevalence of chronic diseases such as Sjogren’s syndrome, HIV, Diabetes, Alzheimer’s disease, and other. In addition, growing geriatric population, increasing adoption of chemotherapy and radiotherapy in cancer treatment, growing health awareness among consumers, rising disposable income, higher healthcare expenditure, and rising initiatives for raising awareness about xerostomia are some other factors expected to drive growth of the global xerostomia therapeutics market.

However, strict regulations and unavailability of effective treatment in some developing and underdeveloped economies are some factors expected to hamper growth of the target market over the forecast period.

Trends:

Prominent players are focusing on getting approval for its products from various regulatory authority. For instance, in May 2018, Prisyna –the oral care division of Synedgen Inc., received 510(k) clearance from the US Food and Drug Administration (FDA) to market its family of Moisyn products for the treatment of xerostomia.

Segmental Analysis:

On the basis of product type, drug segment is expected to dominate the target market, owing to effectiveness, availability, affordability, and higher adoption among end users. On the basis of distribution channel, the retail pharmacies segment is expected to dominate the target market, owing to wide availability of product and online pharmacies based segment is expected to register highest CAGR owing to growing e-commerce sector and increasing penetration of smart phones across the globe.

Regional Analysis:

The market in North America is expected to dominate in the global xerostomia therapeutics market. This is primarily attributed to increasing prevalence of diseases resulting in dry mouth and higher healthcare expenditure in countries in the region.

The market in Asia Pacific is expected to be an emerging market for the global xerostomia therapeutics market, and is expected to register highest CAGR over the forecast period, owing to increasing initiatives for raising awareness, and rising incidences of diseases such as diabetes, HIV, cancer, & Parkinson’s disease that cause dry mouth conditions in countries in the region.

Moreover, the markets in Europe, Latin America and Middle East & Africa are expected to register significant higher revenue growth in the global xerostomia therapeutics market over the forecast period.

GLOBAL XEROSTOMIA THERAPEUTICS MARKET SEGMENTATION:

Segmentation by product type:

• Artificial Saliva
• Salivary Stimulants
• Saliva Substitutes
• Drugs
• Salivary Pens
• Other Product Types (include mouth wash, mouth spray etc.)

 Segmentation by distribution channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

 Segmentation by region:

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa